SGLT2 Inhibition: Uric Acid Excretion Study

Sponsor
Amsterdam UMC, location VUmc
Study ID
NCT05210517
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
35 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The current study investigates the effects of SGLT2 inhibitor empagliflozin on uric acid excretion.

Key Dates

Start date
Oct 1, 2020
Status verified
Apr 2023
Primary completion
Jun 8, 2021
Completion
Sep 1, 2021

Study Design

Enrollment
10 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • No Intervention: No intervention
  • Experimental: Empagliflozin
    Empagliflozin 25 mg once daily for one week
  • Experimental: Benzbromarone
    Benzbromarone 100 mg once daily for one week
  • Experimental: Empagliflozin-Benzbromarone
    Empagliflozin 25 mg once daily for one week combined with Benzbromarone 100 mg once daily for one week

Primary Outcome Measure

plasma uric acid [ Time Frame: 1 week ]

Related Studies